Search - tctmd.com

Displaying 401 - 420 of 463

Sort: Relevancy | Date

News Opinion Editor's Corner

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Shelley Wood

March 28, 2016

News Daily News

Femoral Ultrasound Shows Promise for Atherosclerosis Screening, Risk Assessment

L.A. McKeown

March 15, 2016

News Daily News

Coronary Calcium Goes Beyond CV Risk to Predict a Spate of Other Diseases

Shelley Wood

March 10, 2016

News Daily News

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Michael O'Riordan

March 07, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Michael O'Riordan

January 19, 2016

News Daily News

Many Childhood Cancer Survivors Have Silent Cardiac Conditions

Yael L. Maxwell

January 06, 2016

News Daily News

BP Lowering Reduces Vascular Risk Regardless of Baseline BP and Disease History

Michael O'Riordan

December 27, 2015

News Daily News

For Interventional Trials, Optimal Medical Management May Entail as Much Training as New Techniques

Todd Neale

December 20, 2015

News Daily News

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

Shelley Wood

December 16, 2015

News Opinion Editor's Corner

My Takeaways From AHA 2015

Shelley Wood

November 18, 2015

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor

August 31, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

Advertisement

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Femoral Ultrasound Shows Promise for Atherosclerosis Screening, Risk Assessment

Coronary Calcium Goes Beyond CV Risk to Predict a Spate of Other Diseases

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

TCTMD’s Top 10 Most Popular Stories for January 2016

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure

Many Childhood Cancer Survivors Have Silent Cardiac Conditions

BP Lowering Reduces Vascular Risk Regardless of Baseline BP and Disease History

For Interventional Trials, Optimal Medical Management May Entail as Much Training as New Techniques

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

My Takeaways From AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor

FDA approves Repatha to treat certain patients with high cholesterol

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content